These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 34263067)
1. Noninvasive measure of treatment response in non-alcoholic steatohepatitis: Insights from EMMINENCE and meta-analysis. Davison BA; Edwards C; Loomba R; Harrison SA; Cotter G; Alkhouri N; Koch GG; Dittrich HC JGH Open; 2021 Jul; 5(7):740-749. PubMed ID: 34263067 [TBL] [Abstract][Full Text] [Related]
2. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389 [TBL] [Abstract][Full Text] [Related]
3. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115 [TBL] [Abstract][Full Text] [Related]
4. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study. Zhang H; Rios RS; Boursier J; Anty R; Chan WK; George J; Yilmaz Y; Wong VW; Fan J; Dufour JF; Papatheodoridis G; Chen L; Schattenberg JM; Shi J; Xu L; Wong GL; Lange NF; Papatheodoridi M; Mi Y; Zhou Y; Byrne CD; Targher G; Feng G; Zheng M Chin Med J (Engl); 2023 Feb; 136(3):341-350. PubMed ID: 36848175 [TBL] [Abstract][Full Text] [Related]
5. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852 [TBL] [Abstract][Full Text] [Related]
6. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237 [TBL] [Abstract][Full Text] [Related]
8. Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. Kim JW; Lee CH; Kim BH; Lee YS; Hwang SY; Park BN; Park YS Quant Imaging Med Surg; 2022 Mar; 12(3):1815-1829. PubMed ID: 35284276 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. Jayakumar S; Middleton MS; Lawitz EJ; Mantry PS; Caldwell SH; Arnold H; Mae Diehl A; Ghalib R; Elkhashab M; Abdelmalek MF; Kowdley KV; Stephen Djedjos C; Xu R; Han L; Mani Subramanian G; Myers RP; Goodman ZD; Afdhal NH; Charlton MR; Sirlin CB; Loomba R J Hepatol; 2019 Jan; 70(1):133-141. PubMed ID: 30291868 [TBL] [Abstract][Full Text] [Related]
10. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868 [TBL] [Abstract][Full Text] [Related]
11. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ; JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681 [TBL] [Abstract][Full Text] [Related]
12. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA; Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292 [TBL] [Abstract][Full Text] [Related]
13. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population. Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548 [TBL] [Abstract][Full Text] [Related]
14. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study. Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286 [TBL] [Abstract][Full Text] [Related]
15. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort. De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068 [TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876 [TBL] [Abstract][Full Text] [Related]
18. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. Bril F; Barb D; Lomonaco R; Lai J; Cusi K J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891 [TBL] [Abstract][Full Text] [Related]
19. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560 [TBL] [Abstract][Full Text] [Related]
20. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis. Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]